CRISPR/Cas9 therapeutics: progress and prospects
T Li, Y Yang, H Qi, W Cui, L Zhang, X Fu, X He… - … and Targeted Therapy, 2023 - nature.com
Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated
protein 9 (Cas9) gene-editing technology is the ideal tool of the future for treating diseases …
protein 9 (Cas9) gene-editing technology is the ideal tool of the future for treating diseases …
Trends in micro‐/nanorobotics: materials development, actuation, localization, and system integration for biomedical applications
Abstract Micro‐/nanorobots (m‐bots) have attracted significant interest due to their suitability
for applications in biomedical engineering and environmental remediation. Particularly, their …
for applications in biomedical engineering and environmental remediation. Particularly, their …
Nanoparticles in clinical translation for cancer therapy
The advent of cancer therapeutics brought a paradigm shift from conventional therapy to
precision medicine. The new therapeutic modalities accomplished through the properties of …
precision medicine. The new therapeutic modalities accomplished through the properties of …
Nanoparticle delivery of CRISPR/Cas9 for genome editing
L Duan, K Ouyang, X Xu, L Xu, C Wen, X Zhou… - Frontiers in …, 2021 - frontiersin.org
The emerging clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-
associated system (Cas) gene-editing system represents a promising tool for genome …
associated system (Cas) gene-editing system represents a promising tool for genome …
[HTML][HTML] Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment
Abstract CRISPR/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats-
associated protein 9) is a potent technology for gene-editing. Owing to its high specificity …
associated protein 9) is a potent technology for gene-editing. Owing to its high specificity …
Stimuli-responsive gene delivery nanocarriers for cancer therapy
Gene therapy provides a promising approach in treating cancers with high efficacy and
selectivity and few adverse effects. Currently, the development of functional vectors with …
selectivity and few adverse effects. Currently, the development of functional vectors with …
Polymer-locking fusogenic liposomes for glioblastoma-targeted siRNA delivery and CRISPR–Cas gene editing
Y Zhao, J Qin, D Yu, Y Liu, D Song, K Tian… - Nature …, 2024 - nature.com
In patients with glioblastoma (GBM), upregulated midkine (MDK) limits the survival benefits
conferred by temozolomide (TMZ). RNA interference (RNAi) and CRISPR–Cas9 gene …
conferred by temozolomide (TMZ). RNA interference (RNAi) and CRISPR–Cas9 gene …
Sono‐controllable and ROS‐sensitive CRISPR‐Cas9 genome editing for augmented/synergistic ultrasound tumor nanotherapy
Y Pu, H Yin, C Dong, H **ang, W Wu, B Zhou… - Advanced …, 2021 - Wiley Online Library
The potential of the cluster regularly interspaced short palindromic repeat (CRISPR)‐
associated protein 9 (Cas9)‐based therapeutic genome editing is severely hampered by the …
associated protein 9 (Cas9)‐based therapeutic genome editing is severely hampered by the …
Fast and efficient CRISPR/Cas9 genome editing in vivo enabled by bioreducible lipid and messenger RNA nanoparticles
J Liu, J Chang, Y Jiang, X Meng, T Sun… - Advanced …, 2019 - Wiley Online Library
A main challenge to broaden the biomedical application of CRISPR/Cas9 (clustered
regularly interspaced short palindromic repeat (CRISPR) associated protein 9) genome …
regularly interspaced short palindromic repeat (CRISPR) associated protein 9) genome …
[HTML][HTML] Poly (α-l-lysine)-based nanomaterials for versatile biomedical applications: Current advances and perspectives
M Zheng, M Pan, W Zhang, H Lin, S Wu, C Lu, S Tang… - Bioactive Materials, 2021 - Elsevier
Abstract Poly (α-l-lysine)(PLL) is a class of water-soluble, cationic biopolymer composed of α-
l-lysine structural units. The previous decade witnessed tremendous progress in the …
l-lysine structural units. The previous decade witnessed tremendous progress in the …